Literature DB >> 28602171

Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases.

Jean-Jacques Body1, Geoffrey Quinn2, Susan Talbot3, Emma Booth4, Gaston Demonty4, Aliki Taylor5, Justyna Amelio5.   

Abstract

A systematic literature review was conducted to quantify populations of patients with primary breast cancer in whom bone metastases were detected at study start or during follow-up. Searches were performed in PubMed and EMBASE using terms related to breast cancer and bone metastases. Articles had to have been published 01/01/99-31/12/13, and to report data on the proportion of patients with bone metastases among patients with breast cancer. In total, 156 articles were included in the meta-analysis. A median of 12% of patients with stage I-III breast cancer developed bone metastases during a median follow-up of 60 months. Of patients who developed metastatic disease during follow-up, 55% (median) had bone metastases. Of those with metastatic breast cancer at study start, 58% (median) had bone metastases. These data help to inform on the global burden of bone metastases by defining patient populations that are at risk of developing bone metastases.
Copyright © 2017 Amgen (Europe) GmbH. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bone metastases; Bone metastasis; Breast cancer; Incidence; Prevalence

Mesh:

Year:  2017        PMID: 28602171     DOI: 10.1016/j.critrevonc.2017.04.008

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  22 in total

Review 1.  Fracture risk assessment and clinical decision making for patients with metastatic bone disease.

Authors:  Timothy A Damron; Kenneth A Mann
Journal:  J Orthop Res       Date:  2020-03-23       Impact factor: 3.494

2.  Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.

Authors:  Julie R Gralow; William E Barlow; Alexander H G Paterson; Jieling L M'iao; Danika L Lew; Alison T Stopeck; Daniel F Hayes; Dawn L Hershman; Mark M Schubert; Mark Clemons; Catherine H Van Poznak; Elizabeth C Dees; James N Ingle; Carla I Falkson; Anthony D Elias; Michael J Messino; Jeffrey H Margolis; Shaker R Dakhil; Helen K Chew; Kim Z Dammann; Jeffrey S Abrams; Robert B Livingston; Gabriel N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  2020-07-01       Impact factor: 13.506

3.  Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases.

Authors:  Gregory C Fox; Xinming Su; Jennifer L Davis; Yalin Xu; Kristin A Kwakwa; Michael H Ross; Francesca Fontana; Jingyu Xiang; Alison K Esser; Elizabeth Cordell; Kristen Pagliai; Ha X Dang; Jothilingam Sivapackiam; Sheila A Stewart; Christopher A Maher; Suzanne J Bakewell; James A J Fitzpatrick; Vijay Sharma; Samuel Achilefu; Deborah J Veis; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Mol Cancer Ther       Date:  2021-03-30       Impact factor: 6.261

4.  Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences.

Authors:  Stella D'Oronzo; Walter Gregory; Simon Nicholson; Yuen Khong Chong; Janet Brown; Robert Coleman
Journal:  J Bone Oncol       Date:  2021-05-04       Impact factor: 4.072

5.  Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis.

Authors:  Yue Gong; Jing Zhang; Peng Ji; Hong Ling; Xin Hu; Zhi-Ming Shao
Journal:  Cancer Med       Date:  2018-07-09       Impact factor: 4.452

6.  The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer.

Authors:  Fabio Zugni; Francesca Ruju; Paola Pricolo; Sarah Alessi; Monica Iorfida; Marco Angelo Colleoni; Massimo Bellomi; Giuseppe Petralia
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

7.  The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis.

Authors:  Ricardo Romero-Moreno; Kimberly J Curtis; Thomas R Coughlin; Maria Cristina Miranda-Vergara; Shourik Dutta; Aishwarya Natarajan; Beth A Facchine; Kristen M Jackson; Lukas Nystrom; Jun Li; William Kaliney; Glen L Niebur; Laurie E Littlepage
Journal:  Nat Commun       Date:  2019-09-27       Impact factor: 14.919

8.  A predictive biomarker panel for bone metastases: Liquid biopsy approach.

Authors:  Kinjal P Bhadresha; Maulikkumar Patel; Nayan K Jain; Rakesh M Rawal
Journal:  J Bone Oncol       Date:  2021-06-10       Impact factor: 4.072

9.  Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.

Authors:  Roger von Moos; Jean-Jacques Body; Alex Rider; Jonathan de Courcy; Debajyoti Bhowmik; Francesca Gatta; Guy Hechmati; Yi Qian
Journal:  J Bone Oncol       Date:  2017-11-24       Impact factor: 4.072

10.  Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study.

Authors:  Jin-Feng Huang; Jianfei Shen; Xiao Li; Ramesh Rengan; Nicola Silvestris; Minqi Wang; Lisa Derosa; Xuanqi Zheng; Andrea Belli; Xiao-Lei Zhang; Yan Michael Li; Aimin Wu
Journal:  Ann Transl Med       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.